Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Journal of medicinal chemistry - 12 Apr 2012

Chang Yu-Chung E, Yu XiaXia, Zhang Ying, Tie Yunfeng, Wang Yuan-Fang, Yashchuk Sofiya, Ghosh Arun K, Harrison Robert W, Weber Irene T

Abstract excerpt

GRL-02031 (1) is an HIV-1 protease (PR) inhibitor containing a novel P1' (R)-aminomethyl-2-pyrrolidinone group. Crystal structures at resolutions of 1.25-1.55 Å were analyzed for complexes of 1 with the PR containing major drug resistant mutations, PR(I47V), PR(L76V), PR(V82A), and PR(N88D). Muta...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Catalytic Domain
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Molecular Conformation

Share to Pyrrolidinones

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 22401672
DOI: 10.1021/jm300072d
PMCID: PMC3355519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22401672-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.PMID 22401672Read ↗

Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.Semantic proximity Read ↗

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.Semantic proximity Read ↗

Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.Semantic proximity Read ↗

Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.Semantic proximity Read ↗

Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.Semantic proximity Read ↗

Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV ProteaseSemantic proximity Read ↗

HIV-1 Protease: Structural Perspectives on Drug ResistanceSemantic proximity Read ↗

Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.Semantic proximity Read ↗

Molecular docking-based screening for novel inhibitors of the human immunodeficiency virus type 1 protease that effectively reduce the viral replication in human cellsSemantic proximity Read ↗

HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.Semantic proximity Read ↗

Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.Semantic proximity Read ↗

P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.